<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031689</url>
  </required_header>
  <id_info>
    <org_study_id>Melasma</org_study_id>
    <nct_id>NCT05031689</nct_id>
  </id_info>
  <brief_title>Green Banana Peel Extract for Melasma Treatment</brief_title>
  <official_title>Green Banana Peel Extract for Melasma Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade do Vale do Sapucai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade do Vale do Sapucai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develop and evaluate a pharmaceutical formula based on green banana peel extract for the&#xD;
      treatment of melasma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: to develop and evaluate a pharmaceutical formula based on green banana peel&#xD;
      extract for the treatment of melasma. Methods: it will be a clinical, interventional,&#xD;
      longitudinal study, random sampling, Sample will have 60 patients divided into two groups. In&#xD;
      the Control Group, SPF 30 sunscreen plus pharmaceutical formulation without green banana peel&#xD;
      extract will be used, and in the Study Group, in addition to SPF 30 sunscreen, pharmaceutical&#xD;
      formulation containing green banana peel extract will be used. Patients will undergo&#xD;
      treatment for 90 days, evaluated every 30 days through clinical evaluation and MELASQol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Actual">August 10, 2021</completion_date>
  <primary_completion_date type="Actual">July 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical analysis of Melasma</measure>
    <time_frame>3 months</time_frame>
    <description>Analysis of the skin affected by Melasma will be performed with Melasma Area Severity Index (MASI), the most commonly used outcome measure for melasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life analysis</measure>
    <time_frame>3 months</time_frame>
    <description>Analysis of the quality of life of Melasma patients during the study will be performed using the MELASQol Instrument. It is a useful tool in assessing quality of life in patients with melasma.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Melasma</condition>
  <arm_group>
    <arm_group_label>SPF 30 and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPF 30 and pharmaceutical formulation with green banana peel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Study Group, in addition to the SPF 30 sunscreen, a pharmaceutical formulation containing the extract of the green banana peel will be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract</intervention_name>
    <description>Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract</description>
    <arm_group_label>SPF 30 and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract</intervention_name>
    <description>Study Group In addition to the SPF 30 sunscreen, a pharmaceutical formulation containing green banana peel extract will be used.</description>
    <arm_group_label>SPF 30 and pharmaceutical formulation with green banana peel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients with melasma.&#xD;
&#xD;
          -  Patients aged 18 years or over and 60 years or less.&#xD;
&#xD;
          -  Patients who agree to participate in the study. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have other types of facial hyperchromia.&#xD;
&#xD;
          -  Patients who give up, for any reason, to continue treatment.&#xD;
&#xD;
          -  Patients who have any type of allergic reaction to the product.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana R dos Anjos Mendonça, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vale do Sapucaí University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vale do Sapucaí University</name>
      <address>
        <city>Pouso Alegre</city>
        <state>Minas Gerais</state>
        <zip>37550-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 28, 2021</last_update_submitted>
  <last_update_submitted_qc>August 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade do Vale do Sapucai</investigator_affiliation>
    <investigator_full_name>Adriana Rodrigues dos Anjos Mendonça</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Melasma</keyword>
  <keyword>banana</keyword>
  <keyword>skin</keyword>
  <keyword>sunscreen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunscreening Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

